TNDM Stock Forecast & Price Target

Tandem Diabetes Care has experienced a positive outlook, reflected in its revenue estimates for 2026 and 2027, which show slight increases to $1.111 million and $1.229 million, respectively. The company is projected to regain new patient start growth in the U.S. by approximately 4% year-over-year, driven by increased pharmacy access and MDI conversions, alongside a notable $14 million revenue beat due to strong performance in the U.S. market. Additionally, while new pump shipments saw a decline of approximately 10%, renewals increased by 2%, indicating a stable base of existing users that may contribute to enhanced long-term profitability as the company transitions its user base from DME to pharmacy channels.

Tandem Diabetes Care has experienced significant operating losses since its inception, raising concerns about its ability to achieve sustained profitability moving forward. The company faces potential risks from competitive pressures, flat or declining new patient starts, and challenges in securing favorable pharmacy channel contracts, all of which could hinder its growth prospects. Despite exceeding shipment estimates for its insulin pumps, the year-over-year decline in shipments and lower growth margins relative to competitors indicates a challenging financial landscape for the company.